semaglutide
Fights All-Cause Risk Semaglutide Lags Tirzepatide Wins
Tirzepatide reduces all-cause mortality to 0.9% versus 1.6% for semaglutide, while semaglutide’s weekly 2.4 mg regimen costs about $159 per compounded vial, offering a cost-saving alternative to branded injections. Both drugs belong to the GLP-1 receptor agonist class and are reshaping obesity treatment in the United